Axon Drugs Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 12-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 12-07-2024
- Company Age 34 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 14.21 Cr
as on 12-07-2024
- Satisfied Charges ₹ 0.57 Cr
as on 12-07-2024
- Revenue -2.86%
(FY 2023)
- Profit -18.77%
(FY 2023)
- Ebitda -12.40%
(FY 2023)
- Net Worth 9.28%
(FY 2023)
- Total Assets 0.86%
(FY 2023)
About Axon Drugs
The Corporate was formerly known as Alsalabs Pvt Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹14.21 Cr. The company has closed loans amounting to ₹5.69 M, as per Ministry of Corporate Affairs (MCA) records.
Damodaram Harirajan, Pushpakala Harirajan, and Vikram Harirajan serve as directors at the Company.
- CIN/LLPIN
U24117TN1990PTC019380
- Company No.
019380
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jul 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Axon Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Damodaram Harirajan  | Managing Director | 10-Jul-1990 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vikram Harirajan | Whole-Time Director | 14-Aug-2008 | Current |
| Pushpakala Harirajan | Whole-Time Director | 10-Jul-1990 | Current |
Financial Performance and Corporate Structure Insights of Axon Drugs.
Axon Drugs Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.86% decrease. The company also saw a substantial fall in profitability, with a 18.77% decrease in profit. The company's net worth moved up by a moderate rise of 9.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axon Drugs?
Unlock access to Axon Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Artura Pharmaceuticals Private Limited
Active 14 years 8 monthsDamodaram Harirajan, Pushpakala Harirajan and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 22 Jul 2013 | ₹10.00 Cr | Open |
Indian Overseas Bank Creation Date: 28 Feb 2000 | ₹4.30 M | Open |
Indian Overseas Bank Creation Date: 07 Oct 1999 | ₹0.40 M | Open |
How Many Employees Work at Axon Drugs?
Axon Drugs has a workforce of 53 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axon Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axon Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
